
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 11.000 | 11.000 | 0.000 |
Shares | 94.080 | 94.080 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 41.445 | 22.347 |
Price to Book | 3.196 | 2.714 |
Price to Sales | 5.120 | 3.330 |
Price to Cash Flow | 25.014 | 16.400 |
Dividend Yield | 0.156 | 2.102 |
5 Years Earnings Growth | 4.010 | 6.822 |
Name | Net % | Category Average |
---|---|---|
Healthcare | 99.970 | 97.797 |
Basic Materials | 0.010 | 0.472 |
Industrials | 0.010 | 0.563 |
Technology | 0.010 | 0.380 |
Number of long holdings: 91
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Beigene | CNE100005XT6 | 9.58 | 261.18 | +5.78% | |
Jiangsu Hengrui | CNE0000014W7 | 9.10 | 51.10 | +3.02% | |
InnoCare Pharma | CNE100005P56 | 9.04 | 21.77 | +4.66% | |
Dizal Jiangsu Pharmaceutical | CNE1000055W8 | 7.04 | 57.91 | +0.38% | |
Shouyao Holdings Beijing | CNE1000062V6 | 6.32 | 30.54 | +0.56% | |
Sichuan Biokin Pharmaceutical | CNE100006FN4 | 5.84 | 286.08 | -1.06% | |
Gan Lee Pharmaceuticals | CNE100003ZH1 | 5.61 | 47.69 | -1.63% | |
RemeGen | CNE100005B03 | 5.51 | 50.68 | -0.10% | |
Suzhou Zelgen Biopharma | CNE100003RP1 | 5.00 | 108.11 | +4.87% | |
Hinova Pharmaceuticals | CNE1000059F5 | 4.52 | 39.10 | +1.90% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Penghua Jiangxin Sele Alloc C | 7.3B | 1.91 | -4.28 | - | ||
Penghua HK Bank Index LOF | 4.59B | 11.69 | 13.41 | - | ||
Penghua CSI Guofang Idx Classified | 3.74B | 0.46 | -8.35 | -3.83 | ||
Penghua HongKang mix A | 2.97B | 0.13 | 2.75 | - | ||
Penghua HongKang mix C | 2.97B | 0.10 | 2.65 | - |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review